advocacy

/advocacy

In the 1990’s USA: PSA Screening Reduced Instances of Initial Diagnosis of Metastatic Prostate Cancer By 50%

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and End Results (SEER) Program database. Their analysis included only those men who had been diagnosed with advanced prostate cancer at diagnosis, not of early-stage disease that then progressed to metastasis. In this perspective study the authors describe trends in metastatic prostate cancer prior to and [...]

By | December 4th, 2016|advocacy, Biomarkers and Prognostic Tools, USPTF|0 Comments

The House Passes The 21st Century Cures Act – On To The Senate

Last Wednesday the House passed with a vote of 392 to 26, a medical innovation bill known as the 21st Century Cures Act, aimed at curing diseases, with the measure securing bipartisan support after months of negotiations. The bill’s goals are to speed up the Food and Drug Administration’s approval of new drugs while also investing new money in medical research. The package also includes a range of other healthcare priorities, including $1 billion over two years to fight the epidemic of opioid addiction and $1.8 billion for Vice President Biden’s cancer “moonshot.” The cures legislation also includes a mental health [...]

By | December 1st, 2016|Cancer Moon Shot, FDA, Politics of Cancer, Research, Uncategorized|0 Comments

Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard and invested so many of our tax paid hours on creating. Moving in this direction would have devastating consequences for medical research, including the  Defense Health Research Programs at the Department of Defense (DoD) of which our own Prostate Cancer Research Program (PCRP) is a [...]

By | November 18th, 2016|advocacy, DOD, DOD PCRP, NIH, Research, Uncategorized|0 Comments

Over 20,000 Have Pledged to Boycott CVS & Caremark until they sell Cancer Drugs Again- CVS removing many cancer drugs, including Xtandi, from it’s formulary

Sign pledge to boycott CVS here: http://bit.ly/2gAJlno CVS Pharmacy will hurt many cancer patients by removing dozens of cancer treatment drugs, like leukemia drug Tasigna, prostate cancer drug Xtandi and chemotherapy treatment drug Neupogen, from their formulary, starting in 2017. CVS claims these drugs cost too much. Go ahead and tell that to my insurance provider and Medicare but don’t stop selling these drugs to me and millions of cancer patients. It's our belief that CVS is putting profit above the care of cancer patients. If CVS can make money by selling cheap cosmetics and imported cookies, then, we imagine [...]

By | November 3rd, 2016|advocacy|0 Comments
スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー